The objective was to assess adverse outcomes in relation to the simplified Pulmonary Embolism Severity Index ( PESI ) score in patients treated with rivaroxaban or standard therapy in the phase III EINSTEIN PE study and to evaluate the utility of the simplified PESI score to identify low-risk pulmonary embolism ( PE ) patients .